Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 and Anlotinib in TNBC
NCT03855358Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2019
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of benmelstobart in triple-negative breast cancer (TNBC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Overall Response Rate up to 72 weeks. Status: unknown.
02
Drugs
benmelstobart
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03855358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03855358.